Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease

Inclusion Criteria: * Subject must be ≥18 to ≤35 years of age. * Subject must weigh ≥30 kg. * Subject must have a diagnosis of Sickle Cell Disease. Exclusion Criteria: * Subject must not have had a vaso-occlusive event (VOE) requiring a visit to a healthcare facility within 30 days of screening. * Subject must not have undergone or attempted and failed previous hematopoietic stem cell (HSC) collection. * Subject must not have had a prior autologous or allogeneic transplantation, inclusive of gene therapy. * Male subject must be willing or able to use a highly effective method of contraception for 3 months during and after treatment. * Female subject must not be pregnant or breastfeeding. If sexually active, female subject must be willing or able to use a highly effective method of contraception for 3 months during and after treatment.